Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Pharmaceutical TechnologyEarly data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.HematologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO26: In vivo oncology approaches continue to show promiseNext: Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
